Trastuzumab -DM4 is an antibody-drug conjugate (ADC) formed by conjugating Trastuzumab with DM4 (sulfo-SPDB-DM4) via a cleavable linker. DM4 is a tubulin inhibitor that suppresses cell division. Trastuzumab -DM4 significantly inhibits tumor growth in Trastuzumab -resistant HER2 xenograft tumor models. Trastuzumab -DM4 can be used for the research of HER2-positive breast cancer [1].
In Vivo, Trastuzumab-DM4 (Compound Tmab-SSNPP-DM4) (10 mg/kg; intravenous injection; single administration) significantly inhibits tumor growth in trastuzumab-resistant HER2-overexpressing breast cancer mouse models[1].
References:
[1]. Lewis Phillips GD, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280-9290.
In Vivo, Trastuzumab-DM4 (Compound Tmab-SSNPP-DM4) (10 mg/kg; intravenous injection; single administration) significantly inhibits tumor growth in trastuzumab-resistant HER2-overexpressing breast cancer mouse models[1].
References:
[1]. Lewis Phillips GD, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280-9290.